Jay Arvind Bhanushali, a promoter of Aspira Pathlab & Diagnostics Ltd , acquired 1,387 equity shares through open market transactions between September 11 and September 16, 2026.

The acquisition increased his total shareholding to 7,47,838 shares, representing 7.27% of the company’s voting capital. This marks a marginal rise from his previous holding of 7,46,451 shares, or 7.25%.

Disclosure Details

Bhanushali filed the disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, with the Bombay Stock Exchange on September 16, 2026. The filing confirms that none of the shares held by him are encumbered or pledged.

The company’s total equity share capital remains unchanged at ₹10,29,30,000, divided into 1,02,93,000 equity shares of ₹10 each.

The board of directors of Aspira Pathlab & Diagnostics Limited approved a right issue to raise up to ₹65 crore during its meeting held on September 12, 2026. The capital raise aims to strengthen the company’s financial position through equity or convertible instruments.

The issuance is subject to necessary approvals from shareholders and regulatory bodies, including compliance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and the SEBI Listing Regulations. The company will determine the record date, issue price, and entitlement ratio in due course.

Committee Formation

To oversee the process, the board constituted a Right Issue Committee responsible for finalizing terms and conditions. The committee will also appoint intermediaries and manage other related matters for the issuance.

Regulatory Compliance

The decision was taken under Regulation 30 of the SEBI (LODR) Regulations, 2015. The meeting commenced at 4:00 pm and concluded at 4:30 pm. Managing Director Nikunj Velji Mange signed the disclosure.